SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: squetch who wrote (281)4/22/1998 4:17:00 PM
From: Biomaven  Read Replies (1) of 717
 
squetch,

I think we may see some temporary weakness here as a spillover from Miravant's recent decline in response to a negative article in Forbes. The Forbes article on MRVT was a hatchet job (no earnings for last umpteen years, slow progression through clinical trials etc.) - reminded me of an Abelson column. There was a valid criticism of spending on fancy newspaper ads before any product is ready.

My own view in any case is that the whole PDT market for oncology is an order of magnitude smaller than that for GD-Tex or for Lu-Tex as roto-rooter.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News